Literature DB >> 23757171

[Symptoms and therapy for steroid glaucoma].

F Rüfer1, D Uthoff.   

Abstract

In steroid responders, topical or systemic application of steroids leads to extracellular deposits in the trabecular meshwork which increase trabecular meshwork outflow resistance. 30-40 % of the normal population are steroid responders. About 5 % develop an intraocular pressure (IOP) rise of > 15 mmHg. These patients are termed "high responders". In patients with primary open angle glaucoma (POAG), the proportion of steroid responders sums up to 90 %. The extent of steroid response depends on the kind of steroid used and on the duration of its administration. Dexamethasone has the highest IOP increasing potency. Differential diagnoses are POAG, ocular hypertension, normal tension glaucoma, pseudoexfoliation glaucoma and secondary glaucoma due to different reasons. To make the diagnosis, a detailed anamnesis is crucial. A recompensated IOP after the end of steroid use proves the diagnosis. The treatment of steroid glaucoma includes topical antiglaucoma medications, glaucoma filtration surgery, trabeculotomy, and laser surgery. So far, only few comparative studies on different treatment options have been published on steroid glaucoma. In some cases of therapy-resistant IOP increases following intravitreal or subconjunctival steroid administration, operative removal of the steroids can be considered. A gene therapy treatment of steroid glaucoma is still a topic of research. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23757171     DOI: 10.1055/s-0032-1328472

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  2 in total

1.  In Reply.

Authors:  Andreas Frings
Journal:  Dtsch Arztebl Int       Date:  2017-09-22       Impact factor: 5.594

2.  Transglutaminase binding fusion protein linked to SLPI reduced corneal inflammation and neovascularization.

Authors:  Juan P Salica; Diego Guerrieri; Paulo Maffia; Juan O Croxatto; H Eduardo Chuluyan; Juan E Gallo
Journal:  BMC Ophthalmol       Date:  2015-02-04       Impact factor: 2.209

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.